ClinicalTrials.gg
Active, not recruitingNCT06393712cAPPricorn-1Updated Nov 13, 2026

A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy

A Phase 2 interventional study of Placebo and ALN-APP in Cerebral Amyloid Angiopathy, sponsored by Alnylam Pharmaceuticals. Active, not recruiting at 57 sites in 6 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Alnylam Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

02

Conditions studied

  • Cerebral Amyloid Angiopathy

Keywords

  • CAA
03

In context

Cerebral Amyloid Angiopathy

37 studies on the registry are indexed under Cerebral Amyloid Angiopathy; 8 are open to participants now.

This study's enrollment of 210 is above the median of 60 across 17 interventional studies indexed under Cerebral Amyloid Angiopathy.

Browse Cerebral Amyloid Angiopathy studies →

Lead sponsor

Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria (sporadic CAA patients):

  • Is 50 years or older
  • Has probable CAA per the Boston Criteria Version 2.0

Inclusion Criteria (Dutch-type CAA patients):

  • Is 30 years or older
  • Has known E693Q amyloid precursor protein (APP) gene mutation for Dutch-type CAA

Exclusion Criteria:

  • Moderate or severe stage Alzheimer's disease (AD) or significant cognitive impairment (CI)
  • Has a history of previous clinical intracerebral hemorrhage (ICH) with onset less than 90 days prior to anticipated randomization in the study
  • Has (ALT) or aspartate aminotransferase (AST) >3× (ULN) at Screening
  • Has estimated (eGFR) \<30 mL/min/1.73m\^2 at Screening
  • Has recently received an agent
  • Has had treatment with amyloid-targeting antibody

Note: other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    ALN-APP

    Participants will be administered multiple doses of ALN-APP during the double-blind treatment period and optional open-label extension period.

    Drug: ALN-APP

  • Placebo comparator
    Placebo/ALN-APP

    Participants will be administered multiple doses of placebo during the double-blind treatment period. Participants who continue into the optional open-label extension period will be administered multiple doses of ALN-APP.

    Drug: Placebo · Drug: ALN-APP

Interventions

  • DrugPlacebo

    Placebo will be administered intrathecally

  • ALN-APP will be administered intrathecally

    Also known as: mivelsiran

06

What researchers measure

Primary outcomes

  1. Double-blind Treatment Period: Annualized Rate of New Lobar Cerebral Microbleeds (CMBs) Assessed on Magnetic Resonance Imaging (MRI) of Brain in Patients with Sporadic Cerebral Amyloid Angiopathy (sCAA)

    Time frame: Up to 24 months

Secondary outcomes

  1. Double-blind Treatment Period: Global Rank Based on Severity, Count, Symptom Burden, and Timing of New Clinical Hemorrhagic Events and Hemorrhagic Lesions Assessed on MRI of Brain

    Time frame: Up to 24 months

  2. Double-blind Treatment Period: Change from Baseline Over Time in Cerebrovascular Vasoreactivity Measured by Blood Oxygenation Level Dependent (BOLD) Parameters with Visual-evoked Functional MRI

    Time frame: Up to 24 months

  3. Double-blind Treatment Period: Incidence of New Cerebral Hemorrhagic Lesions and White Matter Hyperintensities Assessed on MRI of Brain

    Time frame: Up to 24 months

  4. Double-blind Treatment Period: Change from Baseline Over Time in the Total Cerebral Amyloid Angiopathy (CAA) Small Vessel Disease Score Assessed on MRI of Brain

    Time frame: Up to 24 months

  5. Double-blind Treatment Period: Change from Baseline in Soluble Amyloid Precursor Protein Alpha (sAPPα) Concentration in Cerebrospinal Fluid (CSF)

    Time frame: Up to 24 months

  6. Double-blind Treatment Period: Change from Baseline in Soluble Amyloid Precursor Protein Beta (sAPPβ) Concentration in CSF

    Time frame: Up to 24 months

  7. Double-blind Treatment Period and Open-label Extension (OLE) Period: Frequency of Adverse Events

    Time frame: Up to 48 months

07

Study locations

57 sites
  • Clinical Trial Site
    Los Angeles, California 90095, United States
  • Clinical Trial Site
    Orange, California 92868, United States
  • Clinical Trial Site
    Palo Alto, California 94304, United States
  • Clinical Trial Site
    Sacramento, California 95816, United States
  • Clinical Trial Site
    San Francisco, California 94114, United States
  • Clinical Trial Site
    Aurora, Colorado 80045, United States
  • Clinical Trial Site
    New Haven, Connecticut 06510, United States
  • Clinical Trial Site
    Gainesville, Florida 32608, United States
  • Clinical Trial Site
    Jacksonville, Florida 32224, United States
  • Clinical Trial Site
    Maitland, Florida 32751, United States
  • Clinical Trial Site
    Naples, Florida 34105, United States
  • Clinical Trial Site
    Chicago, Illinois 60612, United States
  • Clinical Trial Site
    Lexington, Kentucky 40504, United States
  • Clinical Trial Site
    New Orleans, Louisiana 70121, United States
  • Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • Clinical Trial Site
    Plymouth, Massachusetts 02360, United States
  • Clinical Trial Site
    Rochester, Minnesota 55905, United States
  • Clinical Trial Site
    St Louis, Missouri 63110, United States
  • Clinical Trial Site
    Hackensack, New Jersey 07601, United States
  • Clinical Trial Site
    New York, New York 10016, United States
  • Clinical Trial Site
    New York, New York 10029, United States
  • Clinical Trial Site
    New York, New York 10032, United States
  • Clinical Trial Site
    New York, New York 10065, United States
  • Clinical Trial Site
    Durham, North Carolina 27705, United States
  • Clinical Trial Site
    Canton, Ohio 44718, United States
  • Clinical Trial Site
    Cleveland, Ohio 44195, United States
  • Clinical Trial Site
    Abington, Pennsylvania 19001, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Trial Site
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Trial Site
    Dallas, Texas 75243, United States
  • Clinical Trial Site
    Dallas, Texas 75390, United States
  • Clinical Trial Site
    Houston, Texas 77030, United States
  • Clinical Trial Site
    San Antonio, Texas 78229, United States
  • Clinical Trial Site
    Seattle, Washington 98104, United States
  • Clinical Trial Site
    Adelaide, 5000, Australia
  • Clinical Trial Site
    Brisbane, 4029, Australia
  • Clinical Trial Site
    Heidelberg, 3084, Australia
  • Clinical Trial Site
    Nedlands, 6009, Australia
  • Clinical Trial Site
    Parkville, 3050, Australia
  • Clinical Trial Site
    Calgary, T2N 4Z6, Canada
  • Clinical Trial Site
    Hamilton, L8L 2X2, Canada
  • Clinical Trial Site
    Kelowna, V1Y 1Z9, Canada
  • Clinical Trial Site
    Moncton, E1C 2Z3, Canada
  • Clinical Trial Site
    Montreal, H3A 2B4, Canada
  • Clinical Trial Site
    Montreal, H3G 1H9, Canada
  • Clinical Trial Site
    Ottawa, K1Z 1G3, Canada
  • Clinical Trial Site
    Toronto, M3B 2S7, Canada
  • Clinical Trial Site
    Victoria, V8R 1J8, Canada
  • Clinical Trial Site
    Amsterdam, 1081 GN, Netherlands
  • Clinical Trial Site
    Leiden, 2333ZA, Netherlands
  • Clinical Trial Site
    Nijmegen, 6525 GA, Netherlands
  • Clinical Trial Site
    Bern, 3010, Switzerland
  • Clinical Trial Site
    Geneva, 1205, Switzerland
  • Clinical Trial Site
    Sankt Gallen, 9007, Switzerland
  • Clinical Trial Site
    Glasgow, G51 4TF, United Kingdom
  • Clinical Trial Site
    London, SE5 8AF, United Kingdom
  • Clinical Trial Site
    London, WC1N 3BG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Access to Anonymized individual participant data that support these results is made available 12 months after study completion and not less than 12 months after the product and indication have been approved in the US and/or the EU. Access to data may be declined where there is likelihood a patient could be identified or other feasibility issue, where there is a potential conflict of interest, a planned business activities or an actual or potential competitive risk. Data will be provided contingent upon the approval of a research proposal and the execution of a data sharing agreement. Timeframes for data access may vary and can take up to 6 months or more. Requests for access to data can be submitted via the website www.vivli.org. Questions can also be directed to datasharing@alnylam.com.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
May 1, 2024
StartActual
May 17, 2024
Primary completionEst.
Aug 9, 2027
CompletionEst.
Dec 14, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and site details
2 updates, last Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Minor edits only
    + 2 other changes: verification date and site details
  2. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06393712
Responsible party
Sponsor
First posted
May 1, 2024
Start date
May 17, 2024
Primary completion
Aug 9, 2027 (estimated)
Completion
Dec 14, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Medical Director
study director · Alnylam Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mivelsiran

Start the discussion